Regulation of Endothelial Cell-Specific Molecule 1 (Esm-1)- Implications in Diabetes and Cancer
ISEF · 2018 Cellular and Molecular Biology Third Award
Overview
At first glance, diabetic kidney disease and cancer may seem to have little in common besides sharing high mortality rates. Diabetic kidney disease is a condition in which increased glucose levels in the blood downregulates vasodilators in the kidney, thus reducing glomerular filtration rate and allowing leukocyte-induced kidney injury. Cancer is an accumulation of genetic errors that results in uncontrollable cell division. Both leukocyte-induced kidney injury and tumoral immune response are guided by molecular barriers that allow leukocyte-induced damage to glomerular tissue and leukocyte evasion of tumoral sites. The glycan region of Endothelial Cell-Specific Molecule 1 (Esm-1), a glomerular-enriched glycoprotein, binds to LFA-1 to form a molecular barrier blocking leukocyte infiltration in diabetic kidney disease and cancer. To investigate the regulatory mechanisms of Esm-1, luminescence assays were utilized for quantification of gene expression while bioinformatic analysis was used for in silico molecular modeling. The 3’UTR of Esm-1 was verified to stabilize Esm-1 expression and reduce translation by more than half (52.4%) when transfected in relation to the empty vector alone. The G1259?A SNP in the 3’ UTR of Esm-1 reduced Esm-1 translation by nearly half (47.9%). Bioinformatic analysis was conducted to identify the hsa-miR-181 family as a downregulator of Esm-1 translation. A miRNA-based therapeutic was engineered as a regulatory mechanism for Esm-1 expression in both diabetic kidney disease and cancer. Subsequent qPCR experiments quantified hsa-miR-181 expression in vitro. Further inquiry into the regulation of Esm-1 will elucidate the development of novel diabetic kidney disease and cancer therapeutics.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2014
Search for MICA Expression Controlling miRNA in A549 Lung Cancer Cells
ISEF · 2014
Dysregulation of MicroRNA Expression in Diabetes
ISEF · 2023
Possible Use of MicroRNA-488 as a Biomarker for Bad Prognosis in Type 2 Diabetes
ISEF · 2025
Investigating the Synergistic Role of IL-1BETA and TGF-BETA in Endothelial-to- Mesenchymal Transition in Coronary Artery Disease
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair